You can buy or sell Savara and other stocks, options, ETFs, and crypto commission-free!
Savara Inc. Common Stock, also called Savara, is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Read More Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Simply Wall StMar 15
Breakeven On The Horizon For Savara Inc. (NASDAQ:SVRA)
Savara Inc.’s (NASDAQ:SVRA): Savara Inc. operates as an orphan lung disease company. The US$287m market-cap company announced a latest loss of -US$61.5m on 31 December 2018 for its most recent financial year result. As path to profitability is the topic on SVRA’s investors mind, I’ve decided to gauge market sentiment. Below I will provide a high-level summary of the industry analysts’ expectations for SVRA. Check out our latest analysis for Savara SVRA is bordering on breakeven, according to the 7 Biotech...
The Motley FoolMar 13
Savara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript
Savara Inc. (NASDAQ:SVRA) Q4 2018 Earnings Conference Call , 5:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Hello, everyone, and welcome to the Savara Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's website at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction or transm...
Stock Price, News, & Analysis for Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inh...
-$0.36 per share
-$0.29 per share